HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 108 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
American Cancer Society
Grant: RP-16-239-06-COUN
Armstrong Family Foundation
Grant: n/a
FWCI
8.16
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
Additional file 1 of Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
Additional file 2 of Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
Additional file 2 of Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
Additional file 1 of BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells
Additional file 2 of BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells
Additional file 2 of BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells
Additional file 1 of BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells